Abstract

There are no pharmacological disease-modifying treatments that have an enduring effect to mitigate the seizures and comorbidities associated with established chronic temporal lobe epilepsy (TLE). Sodium selenate has been reported to have anti-epileptogenic effects if given before TLE onset. However, the majority of TLE patients already have established epilepsy when they present to the clinic. This study aimed to evaluate for disease modifying effects of sodium selenate treatment in the chronically epileptic rat post-status epilepticus (SE) model of drug-resistant TLE. Wistar rats underwent kainic acid-induced SE or sham. Ten-weeks post-SE, rats were randomly assigned to receive either sodium selenate, levetiracetam, or vehicle subcutaneous infusions continuously for 4 weeks. To evaluate the effects of the treatments, one week of continuous video-EEG was acquired before, during, and 4, 8 weeks post-treatment, followed by behavioral tests. Targeted and untargeted proteomics and metabolomics were performed on post-mortem brain tissue to identify potential pathways associated with modified disease outcomes. Telomere length has emerged as a potential biomarker of chronic brain conditions, was investigated as a novel surrogate marker of epilepsy disease severity in our current study. The results showed that sodium selenate treatment was associated with mitigation of measures of disease severity at 8 weeks post-treatment cessation; reducing the number of spontaneous seizures (p< 0.05), cognitive dysfunction (p< 0.05 in both novel object placement and recognition tasks), and sensorimotor deficits (p< 0.01). Moreover, in the brain post-mortem selenate treatment was associated with increased protein phosphatase 2A (PP2A) expression, reduced hyperphosphorylated tau, and reversed telomere length shortening (p< 0.05). Network medicine integration of multi-omics/ pre-clinical outcomes identified protein-metabolite modules positively correlated with the TLE phenotype. Our results provide evidence that treatment with sodium selenate results in a sustained disease-modifying effect in chronically epileptic rats in the post-KA SE model of TLE, including improved comorbid learning and memory deficits.

Data availability

All the metrodology and results form this work have been included in the manuscrit or as part of the supplementary material.Data has been deposited in Dryad https://doi.org/10.5061/dryad.37pvmcvnd

The following data sets were generated
    1. Casillas-Espinosa PM
    (2022) EEG and multi-omics data
    Dryad Digital Repository, doi:10.5061/dryad.37pvmcvnd.

Article and author information

Author details

  1. Pablo Miguel Casillas-Espinosa

    Department of Neuroscience, Monash University, Melbourne, Australia
    For correspondence
    pablo.casillas-espinosa@monash.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-6199-9415
  2. Alison Anderson

    Department of Neuroscience, Monash University, Melbourne, Australia
    Competing interests
    The authors declare that no competing interests exist.
  3. Anna Harutyunyan

    Department of Neuroscience, Monash University, Melbourne, Australia
    Competing interests
    The authors declare that no competing interests exist.
  4. Crystal Li

    Department of Neuroscience, Monash University, Melbourne, Australia
    Competing interests
    The authors declare that no competing interests exist.
  5. Jiyoon Lee

    Department of Medicine, University of Melbourne, Parkville, Australia
    Competing interests
    The authors declare that no competing interests exist.
  6. Emma L Braine

    Department of Neuroscience, Monash University, Melbourne, Australia
    Competing interests
    The authors declare that no competing interests exist.
  7. Rhys D Brady

    Department of Neuroscience, Monash University, Melbourne, Australia
    Competing interests
    The authors declare that no competing interests exist.
  8. Mujun Sun

    Department of Neuroscience, Monash University, Melbourne, Australia
    Competing interests
    The authors declare that no competing interests exist.
  9. Cheng Huang

    Monash Proteomics and Metabolomics Facility, Monash University, Clayton, Australia
    Competing interests
    The authors declare that no competing interests exist.
  10. Christopher K Barlow

    Monash Proteomics and Metabolomics Facility, Monash University, Clayton, Australia
    Competing interests
    The authors declare that no competing interests exist.
  11. Anup D Shah

    Monash Proteomics and Metabolomics Facility, Monash University, Clayton, Australia
    Competing interests
    The authors declare that no competing interests exist.
  12. Ralf B Schittenhelm

    Monash Proteomics and Metabolomics Facility, Monash University, Clayton, Australia
    Competing interests
    The authors declare that no competing interests exist.
  13. Richelle Mychasiuk

    Department of Neuroscience, Monash University, Melbourne, Australia
    Competing interests
    The authors declare that no competing interests exist.
  14. Nigel C Jones

    Department of Neuroscience, Monash University, Melbourne, Australia
    Competing interests
    The authors declare that no competing interests exist.
  15. Sandy R Shultz

    Department of Medicine, University of Melbourne, Parkville, Australia
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-2525-8775
  16. Terence J O’Brien

    Department of Medicine, University of Melbourne, Parkville, Australia
    For correspondence
    Terence.OBrien@monash.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-7198-8621

Funding

National Health and Medical Research Council (APP1087172)

  • Pablo Miguel Casillas-Espinosa

University of Melbourne (603834)

  • Pablo Miguel Casillas-Espinosa

CIHR Skin Research Training Centre (PTJ - 153051)

  • Richelle Mychasiuk

National Health and Medical Research Council (Level 2 CDF)

  • Sandy R Shultz

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: All procedures were approved by the Florey Animal Ethics Committee (ethics number 16-042-UM), adhered to the Australian code for the care and use of animals for scientific purposes and consistent with ARRIVE 2.0 guidelines

Copyright

© 2023, Casillas-Espinosa et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,228
    views
  • 281
    downloads
  • 19
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Pablo Miguel Casillas-Espinosa
  2. Alison Anderson
  3. Anna Harutyunyan
  4. Crystal Li
  5. Jiyoon Lee
  6. Emma L Braine
  7. Rhys D Brady
  8. Mujun Sun
  9. Cheng Huang
  10. Christopher K Barlow
  11. Anup D Shah
  12. Ralf B Schittenhelm
  13. Richelle Mychasiuk
  14. Nigel C Jones
  15. Sandy R Shultz
  16. Terence J O’Brien
(2023)
Disease-modifying effects of sodium selenate in a model of drug-resistant, temporal lobe epilepsy
eLife 12:e78877.
https://doi.org/10.7554/eLife.78877

Share this article

https://doi.org/10.7554/eLife.78877

Further reading

    1. Medicine
    2. Neuroscience
    Hyeonyoung Min, Yale Y Yang, Yunlei Yang
    Research Article

    It has been well documented that cold is an enhancer of lipid metabolism in peripheral tissues, yet its effect on central nervous system lipid dynamics is underexplored. It is well recognized that cold acclimations enhance adipocyte functions, including white adipose tissue lipid lipolysis and beiging, and brown adipose tissue thermogenesis in mammals. However, it remains unclear whether and how lipid metabolism in the brain is also under the control of ambient temperature. Here, we show that cold exposure predominantly increases the expressions of the lipid lipolysis genes and proteins within the paraventricular nucleus of the hypothalamus (PVH) in male mice. Mechanistically, by using innovatively combined brain-region selective pharmacology and in vivo time-lapse photometry monitoring of lipid metabolism, we find that cold activates cells within the PVH and pharmacological inactivation of cells blunts cold-induced effects on lipid peroxidation, accumulation of lipid droplets, and lipid lipolysis in the PVH. Together, these findings suggest that PVH lipid metabolism is cold sensitive and integral to cold-induced broader regulatory responses.

    1. Medicine
    Mitsuru Sugimoto, Tadayuki Takagi ... Hiromasa Ohira
    Research Article

    Background:

    Post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) is a severe and deadly adverse event following ERCP. The ideal method for predicting PEP risk before ERCP has yet to be identified. We aimed to establish a simple PEP risk score model (SuPER model: Support for PEP Reduction) that can be applied before ERCP.

    Methods:

    This multicenter study enrolled 2074 patients who underwent ERCP. Among them, 1037 patients each were randomly assigned to the development and validation cohorts. In the development cohort, the risk score model for predicting PEP was established via logistic regression analysis. In the validation cohort, the performance of the model was assessed.

    Results:

    In the development cohort, five PEP risk factors that could be identified before ERCP were extracted and assigned weights according to their respective regression coefficients: –2 points for pancreatic calcification, 1 point for female sex, and 2 points for intraductal papillary mucinous neoplasm, a native papilla of Vater, or the pancreatic duct procedures (treated as ‘planned pancreatic duct procedures’ for calculating the score before ERCP). The PEP occurrence rate was 0% among low-risk patients (≤0 points), 5.5% among moderate-risk patients (1–3 points), and 20.2% among high-risk patients (4–7 points). In the validation cohort, the C statistic of the risk score model was 0.71 (95% CI 0.64–0.78), which was considered acceptable. The PEP risk classification (low, moderate, and high) was a significant predictive factor for PEP that was independent of intraprocedural PEP risk factors (precut sphincterotomy and inadvertent pancreatic duct cannulation) (OR 4.2, 95% CI 2.8–6.3; p<0.01).

    Conclusions:

    The PEP risk score allows an estimation of the risk of PEP prior to ERCP, regardless of whether the patient has undergone pancreatic duct procedures. This simple risk model, consisting of only five items, may aid in predicting and explaining the risk of PEP before ERCP and in preventing PEP by allowing selection of the appropriate expert endoscopist and useful PEP prophylaxes.

    Funding:

    No external funding was received for this work.